CD8A and Epstein-Barr virus infection: Infection with this dose mimics symptomatic primary EBV infection, infectious mononucleosis (IM), with high viral loads plateauing 4 weeks after infection, with CD8+ T‐cell lymphocytosis at week 5 and 6 after infection.